<p>Target 2035 is a global initiative that aims to develop a potent and selective pharmacological modulator, such as a chemical probe, for every human protein by 2035. Here, we describe the Target 2035 roadmap to develop computational methods to improve small-molecule hit discovery, which is a key bottleneck in the discovery of chemical probes. Large, publicly available datasets of high-quality protein–small-molecule binding data will be created using affinity-selection mass spectrometry and DNA-encoded chemical library screening. Positive and negative data will be made openly available, and the machine learning community will be challenged to use these data to build models and predict new, diverse small-molecule binders. Iterative cycles of prediction and testing will lead to improved models and more successful predictions. By 2030, Target 2035 will have identified experimentally verified hits for thousands of human proteins and advanced the development of open-access algorithms capable of predicting hits for proteins for which there are not yet any experimental data.</p><p></p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Protein–ligand data at scale to support machine learning

  • Aled M. Edwards,
  • Dafydd R. Owen,
  • Leili Zhang,
  • Damian W. Young,
  • Timothy M. Willson,
  • James Wellnitz,
  • Yanli Wang,
  • Jarrod Walsh,
  • Erik Vernet,
  • Alexander Tropsha,
  • Claudia Tredup,
  • Matthew H. Todd,
  • Amelia Tjaden,
  • Sven Thamm,
  • Michael Sundström,
  • Andreas Steffen,
  • Shaun Stauffer,
  • Lucas Rodrigo de Souza,
  • Min Shen,
  • Kristof Schütt,
  • Lovisa Holmberg Schiavone,
  • Matthieu Schapira,
  • Santha Santhakumar,
  • Kumar Saikatendu,
  • Emma Rivers,
  • Dušan Petrović,
  • Hui Peng,
  • John P. O’Donnell,
  • Susanne Müller-Knapp,
  • Anke Mueller-Fahrnow,
  • Maxwell R. Morgan,
  • Florian Montel,
  • Juan Carlos Mobarec,
  • Maurice Michel,
  • Sofia Melliou,
  • Uta Lessel,
  • Andrew R. Leach,
  • Oliver Krämer,
  • Florian Krieger,
  • Stefan Knapp,
  • Anthony Keefe,
  • Aimo Kannt,
  • Scott A. Johnson,
  • Sandra Häberle,
  • Emily Rose Holzinger,
  • Ingo V. Hartung,
  • Rachel J. Harding,
  • Thomas Hanke,
  • Levon Halabelian,
  • Benjamin Haibe-Kains,
  • Judith Günther,
  • Marie-Aude Guié,
  • Claudia Gordijo,
  • Opher Gileadi,
  • Luca Foschini,
  • Amaury Fernández-Montalván,
  • Ola Engkvist,
  • Madison M. Edwards,
  • Katharina Duerr,
  • David Drewry,
  • Dengfeng Dou,
  • Snezana Djordjevic,
  • Alejandra Solache Diaz,
  • Sergio Martinez Cuesta,
  • Rafael Counago,
  • Wendy D. Cornell,
  • Jesse A. Coker,
  • Djork-Arné Clevert,
  • Timothy Cernak,
  • Nicola A. Burgess-Brown,
  • Peter J. Brown,
  • Mario H. Bengtson,
  • Frances M. Bashore,
  • Dalia Barsyte-Lovejoy,
  • Arrash J. Baghaie,
  • Alison D. Axtman,
  • Cheryl Arrowsmith,
  • Albert A. Antolin,
  • Suzanne Ackloo

摘要

Target 2035 is a global initiative that aims to develop a potent and selective pharmacological modulator, such as a chemical probe, for every human protein by 2035. Here, we describe the Target 2035 roadmap to develop computational methods to improve small-molecule hit discovery, which is a key bottleneck in the discovery of chemical probes. Large, publicly available datasets of high-quality protein–small-molecule binding data will be created using affinity-selection mass spectrometry and DNA-encoded chemical library screening. Positive and negative data will be made openly available, and the machine learning community will be challenged to use these data to build models and predict new, diverse small-molecule binders. Iterative cycles of prediction and testing will lead to improved models and more successful predictions. By 2030, Target 2035 will have identified experimentally verified hits for thousands of human proteins and advanced the development of open-access algorithms capable of predicting hits for proteins for which there are not yet any experimental data.